Patents by Inventor Christoph Lengauer

Christoph Lengauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIK3C2G fusions
    Patent number: 10875930
    Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Nicolas Stransky, Ethan G. Cerami, Joseph L. Kim, Christoph Lengauer
  • PIK3CA fusions
    Patent number: 10669590
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 2, 2020
    Assignee: Blueprint Medicines Corporation
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • NTRK2 FUSIONS
    Publication number: 20190389969
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK. fosion proteins, and fragments of those genes and polypeptides.
    Type: Application
    Filed: August 1, 2019
    Publication date: December 26, 2019
    Applicant: Blueprint Medicines Corporation
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Christoph LENGAUER
  • NTRK2 fusions
    Patent number: 10407509
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK, fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: September 10, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Ethan G. Cerami, Christoph Lengauer
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS
    Publication number: 20190192522
    Abstract: Described herein are selective inhibitors of FGFR4, pharmaceutical compositions including such compounds, and combinations with other therapeutic agents, such as CDK inhibitors (e.g., CDK4/6 inhibitors), and methods of using such combinations.
    Type: Application
    Filed: September 8, 2017
    Publication date: June 27, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Margit HAGEL, Klaus HOEFLICH, Christoph LENGAUER, Nicolas STRANSKY, Christopher WINTER, Lan XU
  • PIK3CA FUSIONS
    Publication number: 20190185942
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 20, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • MET FUSIONS
    Publication number: 20170044621
    Abstract: The invention provides MET gene fusions. MET fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with MET fusions, such as conditions mediated by aberrant MET expression or activity or overexpression of MET.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 16, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ehan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • PIK3CA FUSIONS
    Publication number: 20170044622
    Abstract: The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 16, 2017
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Ethan G. Cerami, Christoph Lengauer, Nicolas Stransky
  • NTRK2 FUSIONS
    Publication number: 20160272725
    Abstract: The invention provides to NTRK (“Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK. fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
    Type: Application
    Filed: July 30, 2014
    Publication date: September 22, 2016
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Christoph LENGAUER
  • PIK3C2G FUSIONS
    Publication number: 20160251446
    Abstract: The invention provides to PIK3C2G (phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma) gene fusions and PIK3C2G fusion proteins. The invention further provides methods of diagnosing and treating diseases or disorders associated with PK3C2G fusions, such as conditions mediated by aberrant PIK3C2G expression or activity, or conditions associated with overexpression of PIK.3C2G.
    Type: Application
    Filed: July 30, 2014
    Publication date: September 1, 2016
    Inventors: Nicolas STRANSKY, Ethan G. CERAMI, Joseph L. KIM, Christoph LENGAUER
  • Securin is required for chromosomal stability in human cells
    Patent number: 7354703
    Abstract: Securin-deficient cells and their isogenic securin-proficient counterparts are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to preferentially inhibit or kill a securin-deficient cell. The association of securin deficiency and chromosomal instability leading to aneuploidy, renders securin an excellent target for chemotherapeutic drug development.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: April 8, 2008
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Prasad Jallepalli, Christoph Lengauer
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 7148009
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: December 12, 2006
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Thymidylate synthase gene and metastasis
    Publication number: 20050202465
    Abstract: Thymidylate synthase (TYMS) gene amplification was observed in 23% of 31 5-FU resistant liver metastases, while no amplification was observed in metastases of patients that had not been treated with 5-FU. Patients with metastases containing TYMS amplification had a substantially shorter median survival (329 days) than those without amplification (1021 days, p<0.01). Genetic amplification of TYMS has important implications for the management of colorectal cancer patients with recurrent disease.
    Type: Application
    Filed: November 24, 2004
    Publication date: September 15, 2005
    Applicant: The Johns Hopkins University
    Inventors: Tian-Li Wang, Luis Diaz, Christoph Lengauer, Victor Velculescu, Kenneth Kinzler, Bert Vogelstein
  • Novel cancer drug screen based on cell cycle uncoupling
    Publication number: 20030108941
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Application
    Filed: December 17, 2002
    Publication date: June 12, 2003
    Applicant: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 6511818
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: January 28, 2003
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Securin is required for chromosomal stability in human cells
    Publication number: 20020137018
    Abstract: Securin-deficient cells and their isogenic securin-proficient counterparts are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to preferentially inhibit or kill a securin-deficient cell. The association of securin deficiency and chromosomal instability leading to aneuploidy, renders securin an excellent target for chemotherapeutic drug development.
    Type: Application
    Filed: March 23, 2001
    Publication date: September 26, 2002
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Prasad Jallepalli, Christoph Lengauer
  • Novel cancer drug screen based on cell cycle uncoupling
    Publication number: 20010012619
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Application
    Filed: April 10, 2001
    Publication date: August 9, 2001
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 5888735
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 30, 1999
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle uncoupling
    Patent number: 5882865
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 16, 1999
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler
  • Cancer drug screen based on cell cycle upcoupling
    Patent number: 5879889
    Abstract: Checkpoint gene-defective human cells are useful for screening potential anti-tumor agents. Potential therapeutic agents are screened for the ability to cause DNA accumulation or cell death in a checkpoint gene-defective human cell.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: March 9, 1999
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler